[go: up one dir, main page]

CL2017003073A1 - Inhibidores de tirosina-cinasas - Google Patents

Inhibidores de tirosina-cinasas

Info

Publication number
CL2017003073A1
CL2017003073A1 CL2017003073A CL2017003073A CL2017003073A1 CL 2017003073 A1 CL2017003073 A1 CL 2017003073A1 CL 2017003073 A CL2017003073 A CL 2017003073A CL 2017003073 A CL2017003073 A CL 2017003073A CL 2017003073 A1 CL2017003073 A1 CL 2017003073A1
Authority
CL
Chile
Prior art keywords
tyrosine kinase
kinase inhibitors
compounds
btk
inhibitors
Prior art date
Application number
CL2017003073A
Other languages
English (en)
Inventor
Timothy D Owens
David Goldstein
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of CL2017003073A1 publication Critical patent/CL2017003073A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Diabetes (AREA)

Abstract

<p>LA PRESENTE DIVULGACIÓN PROPORCIONA COMPUESTOS QUE SON INHIBIDORES DE TIROSINA-CINASAS, EN PARTICULAR INHIBIDORES DE LA TIROSINACINASA DE BRUTON (BTK), Y, POR LO TANTO, SON ÚTILES PARA EL TRATAMIENTO DE ENFERMEDADES QUE SE PUEDEN TRATAR MEDIANTE LA INHIBICIÓN DE BTK TALES COMO EL CÁNCER, ENFERMEDADES AUTOINMUNITARIAS, INFLAMATORIAS Y TROMBOEMBÓLICAS. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN TALES COMPUESTOS Y PROCESOS PARA PREPARAR TALES COMPUESTOS.</p>
CL2017003073A 2015-06-03 2017-12-01 Inhibidores de tirosina-cinasas CL2017003073A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170547P 2015-06-03 2015-06-03
US201562271689P 2015-12-28 2015-12-28

Publications (1)

Publication Number Publication Date
CL2017003073A1 true CL2017003073A1 (es) 2018-06-08

Family

ID=56118090

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003073A CL2017003073A1 (es) 2015-06-03 2017-12-01 Inhibidores de tirosina-cinasas
CL2019002150A CL2019002150A1 (es) 2015-06-03 2019-07-31 Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019002150A CL2019002150A1 (es) 2015-06-03 2019-07-31 Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)

Country Status (33)

Country Link
US (5) US20180162861A1 (es)
EP (3) EP4112618A1 (es)
JP (2) JP6646072B2 (es)
KR (3) KR20240070721A (es)
CN (2) CN106459049B (es)
AU (2) AU2016270973B2 (es)
CA (1) CA2987335A1 (es)
CL (2) CL2017003073A1 (es)
CO (1) CO2017012947A2 (es)
CR (1) CR20170593A (es)
DK (1) DK3303334T3 (es)
DO (1) DOP2017000279A (es)
EA (1) EA039006B1 (es)
ES (1) ES2878030T3 (es)
HK (1) HK1252378A1 (es)
HR (1) HRP20211249T1 (es)
HU (1) HUE055419T2 (es)
IL (2) IL255946A (es)
LT (1) LT3303334T (es)
MX (2) MX383213B (es)
MY (1) MY190548A (es)
PE (1) PE20180521A1 (es)
PH (2) PH12017502203B1 (es)
PL (1) PL3303334T3 (es)
PT (1) PT3303334T (es)
RS (1) RS62290B1 (es)
SG (1) SG10201912443XA (es)
SI (1) SI3303334T1 (es)
TN (1) TN2017000501A1 (es)
TW (2) TWI810582B (es)
UA (1) UA124090C2 (es)
WO (1) WO2016196840A1 (es)
ZA (2) ZA201708667B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159635B (zh) 2012-02-27 2018-09-25 奥雷制药有限公司 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物
HK1211942A1 (en) 2012-09-10 2016-06-03 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
US10226782B2 (en) 2013-11-29 2019-03-12 Daizo Corporation Content-accommodating container, content-accommodating product using same, discharge product, and discharge device
MX372673B (es) 2014-02-21 2020-03-25 Principia Biopharma Inc Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
SI3303334T1 (sl) * 2015-06-03 2021-09-30 Principia Biopharma Inc. Zaviralci tirozin kinaz
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CN108349940B (zh) * 2015-10-14 2021-08-13 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂
EA201892836A1 (ru) 2016-06-29 2019-07-31 Принсипиа Биофарма Инк. Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
JP6920411B2 (ja) * 2016-07-25 2021-08-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ
WO2018156901A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
EP3789040A4 (en) * 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
HUE069830T2 (hu) * 2018-09-13 2025-04-28 Kissei Pharmaceutical Imidazopiridinon vegyület
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
MX2022004427A (es) 2019-10-14 2022-07-12 Principia Biopharma Inc Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
CN115348862A (zh) * 2020-01-20 2022-11-15 建新公司 用于复发型多发性硬化症(rms)的治疗性酪氨酸激酶抑制剂
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022009009A (es) 2020-01-22 2022-08-15 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
WO2021202478A1 (en) * 2020-03-30 2021-10-07 IGIA Pharmaceuticals, Inc. Pediatric formulation of tyrosine kinase inhibitors
US20230270743A1 (en) * 2020-08-10 2023-08-31 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of btk inhibitors in the treatment of diseases
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2022090481A1 (en) 2020-11-02 2022-05-05 Boehringer Ingelheim International Gmbh Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
CN116710452A (zh) * 2020-12-23 2023-09-05 建新公司 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类
JP2024501247A (ja) * 2020-12-23 2024-01-11 ジェンザイム・コーポレーション ４－アミノ－３－（４－フェノキシフェニル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－オン誘導体およびその塩
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022218430A1 (zh) * 2021-04-16 2022-10-20 南京明德新药研发有限公司 咪唑并吡啶类化合物及其应用
CN117295735A (zh) * 2021-04-23 2023-12-26 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
EP4342468A4 (en) * 2021-05-21 2025-06-04 Hangzhou Solipharma Co., Ltd. Tolbrutinib salt and crystal form thereof, manufacturing process therefor, pharmaceutical composition therefrom and use thereof
IL309263A (en) 2021-06-11 2024-02-01 Genzyme Corp Crystalline form of tolbrotinib, method of preparation and use thereof
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
US11793820B2 (en) * 2021-09-24 2023-10-24 Chadwick Donaldson Dry powder foamable formulations for delivery of medicaments through the mucosa
IL313676A (en) 2021-12-21 2024-08-01 Genzyme Corp Crystal forms of (R)-1-(1-acrylopiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imido[4,5-C]pyridin-2(3H)-one and salts their
US20250188076A1 (en) * 2022-03-09 2025-06-12 Teva Pharmaceutical International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
IL317645A (en) * 2022-06-14 2025-02-01 Principia Biopharma Inc Methods for preparing tolbrutinib
IL317768A (en) * 2022-06-22 2025-02-01 Principia Biopharma Inc Methods for preparing tailored BTK inhibitors
IL318093A (en) 2022-06-30 2025-02-01 Principia Biopharma Inc Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN120435291A (zh) 2022-10-11 2025-08-05 普林斯匹亚生物制药公司 用于多发性硬化的治疗性酪氨酸激酶抑制剂
CN118891260B (zh) * 2022-11-07 2025-07-25 天津瑞程健达医药科技有限公司 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物
IL321521A (en) 2022-12-20 2025-08-01 Principia Biopharma Inc Pharmaceutical formulations of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-H1-imidazo[C-4,5]pyridin-2(H3)-one
WO2024163542A2 (en) 2023-02-01 2024-08-08 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis
US20250282777A1 (en) 2024-03-06 2025-09-11 Principia Biopharma Inc. Methods of Making Tolebrutinib

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CA2580343A1 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics, Inc. Imidazoquinoline compounds
US7968563B2 (en) * 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TWI500617B (zh) * 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
CA2836449C (en) * 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
JP2014513728A (ja) * 2011-05-17 2014-06-05 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤としてのアザインドール誘導体
HUE031094T2 (en) * 2011-11-29 2017-07-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
RU2679130C2 (ru) 2012-07-11 2019-02-06 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
HK1211942A1 (en) * 2012-09-10 2016-06-03 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
SI3303334T1 (sl) * 2015-06-03 2021-09-30 Principia Biopharma Inc. Zaviralci tirozin kinaz
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
CN108349940B (zh) 2015-10-14 2021-08-13 淄博百极常生制药有限公司 布鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
EA039006B1 (ru) 2021-11-19
US20250197402A1 (en) 2025-06-19
HK1252378A1 (zh) 2019-05-24
CN106459049A (zh) 2017-02-22
CN113149983B (zh) 2024-03-29
MX395007B (es) 2025-03-24
JP6646072B2 (ja) 2020-02-14
PH12017502203B1 (en) 2022-07-22
TW202210478A (zh) 2022-03-16
KR20180021730A (ko) 2018-03-05
PT3303334T (pt) 2021-07-02
CL2019002150A1 (es) 2019-11-29
AU2016270973B2 (en) 2020-05-14
AU2020203447B2 (en) 2021-04-01
KR102666352B1 (ko) 2024-05-17
EP3912979A1 (en) 2021-11-24
IL279258B (en) 2022-04-01
SI3303334T1 (sl) 2021-09-30
ZA201708667B (en) 2024-07-31
BR112017025850A2 (pt) 2018-08-14
ES2878030T3 (es) 2021-11-18
TWI810582B (zh) 2023-08-01
US20170129890A1 (en) 2017-05-11
CN106459049B (zh) 2020-11-27
IL255946A (en) 2018-01-31
MY190548A (en) 2022-04-27
MX2021006571A (es) 2022-08-25
CO2017012947A2 (es) 2018-03-28
JP2018516935A (ja) 2018-06-28
RS62290B1 (sr) 2021-09-30
EP4112618A1 (en) 2023-01-04
US20230151012A1 (en) 2023-05-18
JP6985433B2 (ja) 2021-12-22
IL279258A (en) 2021-01-31
US20210171526A1 (en) 2021-06-10
KR20220146657A (ko) 2022-11-01
TW201713654A (zh) 2017-04-16
MX383213B (es) 2025-03-13
HUE055419T2 (hu) 2021-11-29
LT3303334T (lt) 2021-07-12
EP3303334B1 (en) 2021-06-02
JP2020073561A (ja) 2020-05-14
PH12021551681A1 (en) 2023-08-23
CN113149983A (zh) 2021-07-23
CR20170593A (es) 2018-05-14
UA124090C2 (uk) 2021-07-21
NZ738458A (en) 2024-10-25
DK3303334T3 (da) 2021-06-28
PE20180521A1 (es) 2018-03-14
CA2987335A1 (en) 2016-12-08
US20180162861A1 (en) 2018-06-14
EP3303334A1 (en) 2018-04-11
SG10201912443XA (en) 2020-02-27
EA201792529A1 (ru) 2018-05-31
NZ776815A (en) 2024-10-25
PL3303334T3 (pl) 2021-11-08
TWI732765B (zh) 2021-07-11
TN2017000501A1 (en) 2019-04-12
KR20240070721A (ko) 2024-05-21
PH12017502203A1 (en) 2018-06-11
HRP20211249T1 (hr) 2021-11-12
WO2016196840A1 (en) 2016-12-08
US9688676B2 (en) 2017-06-27
AU2020203447A1 (en) 2020-06-11
KR102552653B1 (ko) 2023-07-07
AU2016270973A1 (en) 2018-01-18
MX2017015470A (es) 2018-08-15
ZA202401324B (en) 2025-05-28
DOP2017000279A (es) 2018-04-15

Similar Documents

Publication Publication Date Title
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017011851A2 (es) Compuestos novedosos
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
MX361815B (es) Compuestos pirazolopirimidinicos como inhibidores de cinasas.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
MX384259B (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
AR131653A2 (es) Inhibidores de tirosina quinasa
ECSP18000097A (es) Inhibidores de tirosina-cinasas
HK1230963A1 (en) Novel methods for treating cancer